GSK’s Rappuoli and colleagues propose model for sustainable vaccine development

A perspective article in Science Translational Medicine co-authored by GlaxoSmithKline’s Rino Rappuoli argues that to make global vaccine development sustainable, pharmas should contribute early in the process and cede late-stage testing and marketing to manufacturers in developing countries, with the support of government and philanthropic funds.

The idea is a flip of the current model, in which public funders drive vaccine discovery and early development, but more expensive late-stage development is shouldered by pharmas alone. ...